Metabolic remodeling in hypertrophied and failing myocardium: A review

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 313, Issue 3, 2017, Pages H597-H616

  Peterzan, Mark A ^a   Lygate, Craig A ^a   Neubauer, Stefan ^a   Rider, Oliver J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Heart failure; Hypertrophy; Substrate metabolism

Indexed keywords

CARBOHYDRATE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KETONE BODY;

AMPK SIGNALING; CARBOHYDRATE METABOLISM; ENERGY RESOURCE; ENERGY TRANSFER; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HUMAN; METABOLIC REGULATION; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DYNAMICS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; ADAPTATION; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; DISEASE COURSE; ENERGY METABOLISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CARDIOMEGALY; DISEASE PROGRESSION; ENERGY METABOLISM; HEART FAILURE; HUMANS; MYOCARDIUM; PHENOTYPE;

EID: 85029360665     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00731.2016     Document Type: Review

References (287)

1. Ahuja P, Wanagat J, Wang Z, Wang Y, Liem DA, Ping P, Antoshechkin IA, Margulies KB, Maclellan WR. Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation 127:1957-1967, 2013. doi:doi:10.1161/CIRCULATIONAHA.112.001219.
2. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21: 76-83, 1999. doi:10.1038/5013.
3. Akki A, Su J, Yano T, Gupta A, Wang Y, Leppo MK, Chacko VP, Steenbergen C, Weiss RG. Creatine kinase overexpression improves ATP kinetics and contractile function in postischemic myocardium. Am J Physiol Heart Circ Physiol 303: H844-H852, 2012. doi:10.1152/ ajpheart.00268.2012.
4. Aksentijević D, McAndrew DJ, Karlstädt A, Zervou S, Sebag-Montefiore L, Cross R, Douglas G, Regitz-Zagrosek V, Lopaschuk GD, Neubauer S, Lygate CA. Cardiac dysfunction and peri-weaning mortality in malonyl-coenzyme A decarboxylase (MCD) knockout mice as a consequence of restricting substrate plasticity. J Mol Cell Cardiol 75:76-87, 2014. doi:10.1016/j.yjmcc.2014.07.008.
5. Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M, Jonker JW, Giles W, Naviaux RK, Giguère V, Evans RM. ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007. doi:10.1016/j.cmet.2007.06.007.
6. Alesutan I, Voelkl J, Stöckigt F, Mia S, Feger M, Primessnig U, Sopjani M, Munoz C, Borst O, Gawaz M, Pieske B, Metzler B, Heinzel F, Schrickel JW, Lang F. AMP-activated protein kinase α1 regulates cardiac gap junction protein connexin 43 and electrical remodeling following pressure overload. Cell Physiol Biochem 35: 406-418, 2015. doi:10.1159/000369706.
7. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol Heart Circ Physiol 267:H742-H750, 1994.
8. Amorim PA, Nguyen TD, Shingu Y, Schwarzer M, Mohr FW, Schrepper A, Doenst T. Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression. J Thorac Cardiovasc Surg 140: 1160-1167, 2010. doi:10.1016/j.jtcvs.2010.08.003.
9. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, Seidman CE. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109: 357-362, 2002. doi:10.1172/JCI0214571.
10. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu P-H, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM. Transcriptional coactivator PGC-1 α controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271, 2005. doi:10.1016/j.cmet.2005.03.002.
11. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α. Proc Natl Acad Sci USA 103: 10086-10091, 2006. doi:10.1073/pnas.0603615103.
12. Arbustini E, Diegoli M, Fasani R, Grasso M, Morbini P, Banchieri N, Bellini O, Dal Bello B, Pilotto A, Magrini G, Campana C, Fortina P, Gavazzi A, Narula J, Viganò M. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol 153: 1501-1510, 1998. doi:10.1016/S0002-9440(10)65738-0.
13. Athéa Y, Viollet B, Mateo P, Rousseau D, Novotova M, Garnier A, Vaulont S, Wilding JR, Grynberg A, Veksler V, Hoerter J, Ventura-Clapier R. AMP-activated protein kinase α2 deficiency affects cardiac cardiolipin homeostasis and mitochondrial function. Diabetes 56: 786-794, 2007. doi:10.2337/db06-0187.
14. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The failing heart relies on ketone bodies as a fuel. Circulation 133: 698-705, 2016. doi:10.1161/CIRCULATIONAHA.115.017355.
15. Augustus AS, Buchanan J, Park T-S, Hirata K, Noh HL, Sun J, Homma S, D’armiento J, Abel ED, Goldberg IJ. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 281: 8716-8723, 2006. doi:10.1074/ jbc.M509890200.
16. Bache RJ, Zhang J, Murakami Y, Zhang Y, Cho YK, Merkle H, Gong G, From AHL, Ugurbil K. Myocardial oxygenation at high workstates in hearts with left ventricular hypertrophy. Cardiovasc Res 42: 616-626, 1999. doi:10.1016/S0008-6363(98)00332-0.
17. Bache RJ, Zhang J, Path G, Merkle H, Hendrich K, From AH, Ugurbil K. High-energy phosphate responses to tachycardia and inotropic stimulation in left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 266: H1959-H1970, 1994.
18. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol Cell Physiol 258: C377-C389, 1990.
19. Balaban RS, Kantor HL, Katz LA, Briggs RW. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science 232: 1121-1123, 1986. doi:10.1126/science.3704638.
20. Barclay CJ. Getting energy to where it is required is a problem in the failing heart. J Physiol 586: 5037-5038, 2008. doi:10.1113/jphysiol.2008.163246.
21. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J Clin Invest 105: 1723-1730, 2000. doi:10.1172/JCI9056.
22. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10: 238-245, 2000. doi:10.1016/ S1050-1738(00)00077-3.
23. Barish GD, Narkar VA, Evans RM. PPAR δ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597, 2006. doi:10.1172/ JCI27955.
24. Barth AS, Kumordzie A, Colantuoni C, Margulies KB, Cappola TP, Tomaselli GF. Reciprocal regulation of metabolic and signaling pathways. BMC Genomics 11: 197, 2010. doi:10.1186/1471-2164-11-197.
25. Barth AS, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli GF. Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet 4: 475-483, 2011. doi:10.1161/CIRCGENETICS.110.957571.
26. Bedi KC Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133: 706-716, 2016. doi:10.1161/CIRCULATIONAHA.115.017545.
27. Ben Cheikh R, Guendouz A, Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effects of different lipid substrates. Am J Physiol Heart Circ Physiol 266: H2090-H2097, 1994.
28. Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, Pypaert M, Young LH, Semenkovich CF, Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 281: E1340-E1346, 2001.
29. 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy:evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10: 1215-1220, 2001. doi:10.1093/hmg/10.11.1215.
30. Bornstein B, Huertas R, Ochoa P, Campos Y, Guillen F, Garesse R, Arenas J. Mitochondrial gene expression and respiratory enzyme activities in cardiac diseases. Biochim Biophys Acta 1406: 85-90, 1998. doi:10.1016/S0925-4439(97)00076-8.
31. Bottomley PA, Panjrath GS, Lai S, Hirsch GA, Wu K, Najjar SS, Steinberg A, Gerstenblith G, Weiss RG. Metabolic rates of ATP transfer through creatine kinase (CK flux) predict clinical heart failure events and death. Sci Transl Med 5: 215re3, 2013. doi:10.1126/ scitranslmed.3007328.
32. Bottomley PA, Wu KC, Gerstenblith G, Schulman SP, Steinberg A, Weiss RG. Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study. Circulation 119: 1918-1924, 2009. doi:10.1161/ CIRCULATIONAHA.108.823187.
33. Branovets J, Sepp M, Kotlyarova S, Jepihhina N, Sokolova N, Aksentijevic D, Lygate CA, Neubauer S, Vendelin M, Birkedal R. Unchanged mitochondrial organization and compartmentation of highenergy phosphates in creatine-deficient GAMT/ mouse hearts. Am J Physiol Heart Circ Physiol 305: H506-H520, 2013. doi:10.1152/ ajpheart.00919.2012.
34. Bugger H, Chemnitius JM, Doenst T. Differential changes in respiratory capacity and ischemia tolerance of isolated mitochondria from atrophied and hypertrophied hearts. Metabolism 55: 1097-1106, 2006. doi:10.1016/j.metabol.2006.04.005.
35. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, Nguyen TD, Mohr FW, Khalimonchuk O, Weimer BC, Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res 85: 376-384, 2010. doi:10.1093/cvr/cvp344.
36. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP. Nuclear receptors PPARbeta/δ and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 117: 3930-3939, 2007. doi:10.1172/JCI32578.
37. 2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 292: H3136-H3147, 2007. doi:10.1152/ajpheart.00683.2006.
38. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250, 2004. doi:10.1038/nm1116.
39. Chidsey CA, Weinbach EC, Pool PE, Morrow AG. Biochemical studies of energy production in the failing human heart. J Clin Invest 45:40-50, 1966. doi:10.1172/JCI105322.
40. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol 26:1371-1375, 1994. doi:10.1006/jmcc.1994.1155.
41. 31 P magnetic resonance spectroscopy. Lancet 338: 973-976, 1991. doi:10.1016/0140-6736(91)91838-L.
42. Cooney GJ, Taegtmeyer H, Newsholme EA. Tricarboxylic acid cycle flux and enzyme activities in the isolated working rat heart. Biochem J 200: 701-703, 1981. doi:10.1042/bj2000701.
43. Cooper MP. Interplay of mitochondrial biogenesis and oxidative stress in heart failure. Circulation 127: 1932-1934, 2013. doi:10.1161/CIRCULATIONAHA.113.003177.
44. Cordero-Reyes AM, Gupte AA, Youker KA, Loebe M, Hsueh WA, Torre-Amione G, Taegtmeyer H, Hamilton DJ. Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function. J Mol Cell Cardiol 68: 98-105, 2014. doi:10.1016/j.yjmcc.2013.12.029.
45. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304: H1060-H1076, 2013. doi:10.1152/ajpheart.00646.2012.
46. Crozatier B, Badoual T, Boehm E, Ennezat P-V, Guenoun T, Su J, Veksler V, Hittinger L, Ventura-Clapier R. Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice. FASEB J 16: 653-660, 2002. doi:10.1096/fj.01-0652com.
47. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40:271-277, 2002. doi:10.1016/S0735-1097(02)01967-8.
48. Degens H, de Brouwer KFJ, Gilde AJ, Lindhout M, Willemsen PHM, Janssen BJ, van der Vusse GJ, van Bilsen M. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res Cardiol 101: 17-26, 2006. doi:10.1007/s00395-005-0549-0.
49. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Dávila-Román VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension 41: 83-87, 2003. doi:10.1161/01.HYP.0000047668.48494.39.
50. de las Fuentes L, Soto PF, Cupps BP, Pasque MK, Herrero P, Gropler RJ, Waggoner AD, Dávila-Román VG. Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol 13: 369-377, 2006. doi:10.1016/j.nuclcard.2006.01.021.
51. De Sousa E, Veksler V, Minajeva A, Kaasik A, Mateo P, Mayoux E, Hoerter J, Bigard X, Serrurier B, Ventura-Clapier R. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res 85:68-76, 1999. doi:10.1161/01.RES.85.1.68.
52. Des Rosiers C, Labarthe F, Lloyd SG, Chatham JC. Cardiac anaplerosis in health and disease: food for thought. Cardiovasc Res 90:210-219, 2011. doi:10.1093/cvr/cvr055.
53. Dodd MS, Ball DR, Schroeder MA, Le Page LM, Atherton HJ, Heather LC, Seymour A-M, Ashrafian H, Watkins H, Clarke K, Tyler DJ. In vivo alterations in cardiac metabolism and function in the spontaneously hypertensive rat heart. Cardiovasc Res 95: 69-76, 2012. doi:10.1093/cvr/cvs164.
54. Doenst T, Goodwin GW, Cedars AM, Wang M, Stepkowski S, Taegtmeyer H. Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro. Metabolism 50: 1083-1090, 2001. doi:10.1053/meta.2001.25605.
55. Doenst T, Pytel G, Schrepper A, Amorim P, Färber G, Shingu Y, Mohr FW, Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86: 461-470, 2010. doi:10.1093/cvr/ cvp414.
56. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JRB. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 1832: 1723-1733, 2013. doi:10.1016/j.bbadis.2013.05.018.
57. Dörner A, Schulze K, Rauch U, Schultheiss HP. Adenine nucleotide translocator in dilated cardiomyopathy: pathophysiological alterations in expression and function. Mol Cell Biochem 174: 261-269, 1997. doi:10.1023/A:1006825028170.
58. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguère V. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and γ. Cell Metab 5: 345-356, 2007. doi:10.1016/j.cmet.2007.03.007.
59. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-α transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-α activators. Circulation 121: 426-435, 2010. doi:10.1161/CIRCULATIONAHA.109.888735.
60. Dzeja PP, Terzic A. Phosphotransfer networks and cellular energetics. J Exp Biol 206: 2039-2047, 2003. doi:10.1242/jeb.00426.
61. Dzeja PP, Vitkevicius KT, Redfield MM, Burnett JC, Terzic A. Adenylate kinase-catalyzed phosphotransfer in the myocardium: increased contribution in heart failure. Circ Res 84: 1137-1143, 1999. doi:10.1161/01.RES.84.10.1137.
62. el Alaoui-Talibi Z, Landormy S, Loireau A, Moravec J. Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am J Physiol Heart Circ Physiol 262: H1068-H1074, 1992.
63. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226-1231, 2003.
64. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002. doi:10.1172/ JCI0214080.
65. Friehs I, Moran AM, Stamm C, Colan SD, Takeuchi K, Cao-Danh H, Rader CM, McGowan FX, del Nido PJ. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation Suppl 100: II187-II193, 1999. doi:10.1161/01.CIR.100.suppl_2.II-187.
66. From AHL, Zimmer SD, Michurski SP, Mohanakrishnan P, Ulstad VK, Thoma WJ, Uğurbil K. Regulation of the oxidative phosphorylation rate in the intact cell. Biochemistry 29: 3731-3743, 1990. doi:10.1021/bi00467a020.
67. Fu YN, Xiao H, Ma XW, Jiang SY, Xu M, Zhang YY. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin 32: 879-887, 2011. doi:10.1038/aps.2010.229.
68. Garnier A, Zoll J, Fortin D, N’Guessan B, Lefebvre F, Geny B, Mettauer B, Veksler V, Ventura-Clapier R. Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II. Circ Heart Fail 2:342-350, 2009. doi:10.1161/CIRCHEARTFAILURE.108.812099.
69. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. Peroxisome proliferator-activated receptor (PPAR)α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518-524, 2003. doi:10.1161/01.RES.0000060700.55247.7C.
70. 2+ in the regulation of cellular energetics. Biochemistry 51: 2959-2973, 2012. doi:10.1021/bi2018909.
71. Gong G, Liu J, Liang P, Guo T, Hu Q, Ochiai K, Hou M, Ye Y, Wu X, Mansoor A, From AHL, Ugurbil K, Bache RJ, Zhang J. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 285: H541-H548, 2003. doi:10.1152/ajpheart.01142.2002.
72. Griffiths ER, Friehs I, Scherr E, Poutias D, McGowan FX, Del Nido PJ. Electron transport chain dysfunction in neonatal pressure-overload hypertrophy precedes cardiomyocyte apoptosis independent of oxidative stress. J Thorac Cardiovasc Surg 139: 1609-1617, 2010. doi:10.1016/j. jtcvs.2009.08.060.
73. Gupta A, Akki A, Wang Y, Leppo MK, Chacko VP, Foster DB, Caceres V, Shi S, Kirk JA, Su J, Lai S, Paolocci N, Steenbergen C, Gerstenblith G, Weiss RG. Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest 122: 291-302, 2012. doi:10.1172/ JCI57426.
74. Gupta A, Chacko VP, Schär M, Akki A, Weiss RG. Impaired ATP kinetics in failing in vivo mouse heart. Circ Cardiovasc Imaging 4:42-50, 2011. doi:10.1161/CIRCIMAGING.110.959320.
75. Gupta A, Rohlfsen C, Leppo MK, Chacko VP, Wang Y, Steenbergen C, Weiss RG. Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLoS One 8: e74675, 2013. doi:10.1371/journal.pone.0074675.
76. Gupte AA, Hamilton DJ, Cordero-Reyes AM, Youker KA, Yin Z, Estep JD, Stevens RD, Wenner B, Ilkayeva O, Loebe M, Peterson LE, Lyon CJ, Wong STC, Newgard CB, Torre-Amione G, Taegtmeyer H, Hsueh WA. Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ Cardiovasc Genet 7:266-276, 2014. doi:10.1161/CIRCGENETICS.113.000404.
77. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008. doi:10.1016/j.molcel.2008.03.003.
78. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz T, Pravenec M, Abumrad NA. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276:23661-23666, 2001. doi:10.1074/jbc.M100942200.
79. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, Larsson N-G. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci USA 101: 3136-3141, 2004. doi:10.1073/ pnas.0308710100.
80. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103: 670-677, 2001. doi:10.1161/01.CIR.103.5.670.
81. Hardie DG. AMPK-sensing energy while talking to other signaling pathways. Cell Metab 20: 939-952, 2014. doi:10.1016/j.cmet.2014.09.013.
82. Hardie DG. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim Biophys Acta 1123: 231-238, 1992. doi:10.1016/0005-2760(92)90001-C.
83. He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126: 1705-1716, 2012. doi:10.1161/ CIRCULATIONAHA.111.075978.
84. Heather LC, Cole MA, Lygate CA, Evans RD, Stuckey DJ, Murray AJ, Neubauer S, Clarke K. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res 72: 430-437, 2006. doi:10.1016/j.cardiores.2006.08.020.
85. Hochachka PW, Clark CM, Holden JE, Stanley C, Ugurbil K, Menon RS. 31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Proc Natl Acad Sci USA 93: 1215-1220, 1996.
86. Horn M, Remkes H, Strömer H, Dienesch C, Neubauer S. Chronic phosphocreatine depletion by the creatine analogue β-guanidinopropionate is associated with increased mortality and loss of ATP in rats after myocardial infarction. Circulation 104: 1844-1849, 2001. doi:10.1161/ hc3901.095933.
87. How O-J, Aasum E, Kunnathu S, Severson DL, Myhre ESP, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol 288: H2979-H2985, 2005. doi:10.1152/ajpheart.00084.2005.
88. Hu Q, Wang X, Lee J, Mansoor A, Liu J, Zeng L, Swingen C, Zhang G, Feygin J, Ochiai K, Bransford TL, From AHL, Bache RJ, Zhang J. Profound bioenergetic abnormalities in peri-infarct myocardial regions. Am J Physiol Heart Circ Physiol 291: H648-H657, 2006. doi:10.1152/ajpheart.01387.2005.
89. Hu X, Xu X, Huang Y, Fassett J, Flagg TP, Zhang Y, Nichols CG, Bache RJ, Chen Y. Disruption of sarcolemmal ATP-sensitive potassium channel activity impairs the cardiac response to systolic overload. Circ Res 103: 1009-1017, 2008. doi:10.1161/CIRCRESAHA.107.170795.
90. Hu X, Xu X, Lu Z, Zhang P, Fassett J, Zhang Y, Xin Y, Hall JL, Viollet B, Bache RJ, Huang Y, Chen Y. AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development. Hypertension 58: 696-703, 2011. doi:10.1161/HYPERTENSIONAHA.111.174128.
91. Hügel S, Horn M, de Groot M, Remkes H, Dienesch C, Hu K, Ertl G, Neubauer S. Effects of ACE inhibition and β-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol Heart Circ Physiol 277: H2167-H2175, 1999.
92. Huss JM, Garbacz WG, Xie W. Constitutive activities of estrogenrelated receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta 1852: 1912-1927, 2015. doi:10.1016/j.bbadis.2015.06.016.
93. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguère V, Murphy E, Kelly DP. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab 6: 25-37, 2007. doi:10.1016/j. cmet.2007.06.005.
94. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568-578, 2004. doi:10.1161/01.RES.0000141774.29937. e3.
95. Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. Estrogen-related receptor α directs peroxisome proliferator-activated receptor α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24: 9079-9091, 2004. doi:10.1128/MCB.24.20.9079-9091.2004.
96. Ingwall J. Adaptive and maladaptive processes: is cardiac failure a consequence of decreased energy reserve? Circulation 87: VII58-VII62, 1993.
97. Ingwall JS. ATP and the Heart. New York: Springer Science & Business Media, 2002. doi:10.1007/978-1-4615-1093-2.
98. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 81: 412-419, 2009. doi:10.1093/cvr/cvn301.
99. Ingwall JS. The hypertrophied myocardium accumulates the MB-creatine kinase isozyme. Eur Heart J 5, Suppl F: 129-139, 1984. doi:10.1093/eurheartj/5.suppl_F.129.
100. Ingwall JS, Atkinson DE, Clarke K, Fetters JK. Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. Eur Heart J 11, Suppl B: 108-115, 1990. doi:10.1093/ eurheartj/11.suppl_B.108.
101. Jarreta D, Orús J, Barrientos A, Miró O, Roig E, Heras M, Moraes CT, Cardellach F, Casademont J. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc Res 45: 860-865, 2000. doi:10.1016/S0008-6363(99)00388-0.
102. Jessen N, Koh H-J, Folmes CD, Wagg C, Fujii N, Løfgren B, Wolf CM, Berul CI, Hirshman MF, Lopaschuk GD, Goodyear LJ. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta 1802: 593-600, 2010. doi:10.1016/j.bbadis.2010.04.008.
103. Joubert F, Wilding JR, Fortin D, Domergue-Dupont V, Novotova M, Ventura-Clapier R, Veksler V. Local energetic regulation of sarcoplasmic and myosin ATPase is differently impaired in rats with heart failure. J Physiol 586: 5181-5192, 2008. doi:10.1113/jphysiol.2008.157677.
104. Kaasik A, Veksler V, Boehm E, Novotova M, Minajeva A, Ventura-Clapier R. Energetic crosstalk between organelles: architectural integration of energy production and utilization. Circ Res 89: 153-159, 2001. doi:10.1161/hh1401.093440.
105. Kaasik A, Veksler V, Boehm E, Novotova M, Ventura-Clapier R. From energy store to energy flux: a study in creatine kinase-deficient fast skeletal muscle. FASEB J 17: 708-710, 2003. doi:10.1096/fj.02-0684fje.
106. Kagaya Y, Kanno Y, Takeyama D, Ishide N, Maruyama Y, Takahashi T, Ido T, Takishima T. Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study. Circulation 81: 1353-1361, 1990. doi:10.1161/01.CIR.81.4.1353.
107. Kapelko VI, Kupriyanov VV, Novikova NA, Lakomkin VL, Steinschneider AYa, Severina MYu, Veksler VI, Saks VA. The cardiac contractile failure induced by chronic creatine and phosphocreatine deficiency. J Mol Cell Cardiol 20: 465-479, 1988. doi:10.1016/S0022-2828(88)80074-9.
108. Karamanlidis G, Bautista-Hernandez V, Fynn-Thompson F, Del Nido P, Tian R. Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circ Heart Fail 4: 707-713, 2011. doi:10.1161/CIRCHEARTFAILURE.111.961474.
109. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab 18: 239-250, 2013. doi:10.1016/j.cmet.2013.07.002.
110. Kassiotis C, Rajabi M, Taegtmeyer H. Metabolic reserve of the heart:the forgotten link between contraction and coronary flow. Prog Cardiovasc Dis 51: 74-88, 2008. doi:10.1016/j.pcad.2007.11.005.
111. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, Iwanaga Y, Narazaki M, Matsuda T, Soga T, Kita T, Kimura T, Shioi T. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420-430, 2010. doi:10.1161/CIRCHEARTFAILURE.109.888479.
112. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122: 2727-2735, 2010. doi:10.1161/CIRCULATIONAHA.110.942268.
113. Kemi OJ, Høydal MA, Haram PM, Garnier A, Fortin D, Ventura-Clapier R, Ellingsen O. Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan. Cardiovasc Res 76: 91-99, 2007. doi:10.1016/j.cardiores.2007.06.008.
114. Khan RS, Lin Y, Hu Y, Son N-H, Bharadwaj KG, Palacios C, Chokshi A, Ji R, Yu S, Homma S, Schulze PC, Tian R, Goldberg IJ. Rescue of heart lipoprotein lipase-knockout mice confirms a role for triglyceride in optimal heart metabolism and function. Am J Physiol Endocrinol Metab 305: E1339-E1347, 2013. doi:10.1152/ajpendo.00349.2013.
115. Kienesberger PC, Pulinilkunnil T, Sung MMY, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JRB. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 32: 740-750, 2012. doi:10.1128/MCB.06470-11.
116. Kim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K, Young LH. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 51:24-32, 2011. doi:10.1016/j.yjmcc.2011.03.003.
117. Kim GE, Ross JL, Xie C, Su KN, Zaha VG, Wu X, Palmeri M, Ashraf M, Akar JG, Russell KS, Akar FG, Young LH. LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation. Cardiovasc Res 108: 197-208, 2015. doi:10.1093/cvr/cvv212.
118. Kim M, Hunter RW, Garcia-Menendez L, Gong G, Yang Y-Y, Kolwicz SC Jr, Xu J, Sakamoto K, Wang W, Tian R. Mutation in the γ2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 114: 966-975, 2014. doi:10.1161/CIRCRESAHA.114.302364.
119. Kim M, Shen M, Ngoy S, Karamanlidis G, Liao R, Tian R. AMPK isoform expression in the normal and failing hearts. J Mol Cell Cardiol 52: 1066-1073, 2012. doi:10.1016/j.yjmcc.2012.01.016.
120. Kohlhaas M, Maack C. Calcium release microdomains and mitochondria. Cardiovasc Res 98: 259-268, 2013. doi:10.1093/cvr/cvt032.
121. Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res 111: 728-738, 2012. doi:10.1161/CIRCRESAHA.112.268128.
122. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, Kang PM. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 21: 34-42, 2005. doi:10.1152/physiolgenomics.00226.2004.
123. 2+ loss in cardiac muscle: different efficiencies of different energy sources. Cardiovasc Res 83: 89-96, 2009. doi:10.1093/cvr/cvp125.
124. Kwong JQ, Molkentin JD. Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metab 21:206-214, 2015. doi:10.1016/j.cmet.2014.12.001.
125. Labarthe F, Khairallah M, Bouchard B, Stanley WC, Des Rosiers C. Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. Am J Physiol Heart Circ Physiol 288: H1425-H1436, 2005. doi:10.1152/ajpheart.00722.2004.
126. La Gerche A. The potential cardiotoxic effects of exercise. Can J Cardiol 32: 421-428, 2016. doi:10.1016/j.cjca.2015.11.010.
127. Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J, Kapoor K, Koves TR, Stevens R, Ilkayeva OR, Vega RB, Attie AD, Muoio DM, Kelly DP. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 7: 1022-1031, 2014. doi:10.1161/CIRCHEARTFAILURE.114.001469.
128. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van der Wall EE, de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99: 2261-2267, 1999. doi:10.1161/01.CIR.99.17.2261.
129. Lee SH, Doliba N, Osbakken M, Oz M, Mancini D. Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 116: 344-349, 1998. doi:10.1016/S0022-5223(98)70136-9.
130. Lehman JJ, Boudina S, Banke NH, Sambandam N, Han X, Young DM, Leone TC, Gross RW, Lewandowski ED, Abel ED, Kelly DP. The transcriptional coactivator PGC-1α is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol 295: H185-H196, 2008. doi:10.1152/ ajpheart.00081.2008.
131. Lehman JJ, Kelly DP. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol 29: 339-345, 2002. doi:10.1046/j.1440-1681.2002.03655.x.
132. Lei B, Lionetti V, Young ME, Chandler MP, d’Agostino C, Kang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, Recchia FA. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36: 567-576, 2004. doi:10.1016/j.yjmcc.2004.02.004.
133. Lemieux H, Semsroth S, Antretter H, Höfer D, Gnaiger E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int J Biochem Cell Biol 43: 1729-1738, 2011. doi:10.1016/j.biocel.2011.08.008.
134. Lewandowski ED, O’donnell JM, Scholz TD, Sorokina N, Buttrick PM. Recruitment of NADH shuttling in pressure-overloaded and hypertrophic rat hearts. Am J Physiol Cell Physiol 292: C1880-C1886, 2007. doi:10.1152/ajpcell.00576.2006.
135. Li H, Wang J, Wilhelmsson H, Hansson A, Thorén P, Duffy J, Rustin P, Larsson N-G. Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci USA 97: 3467-3472, 2000.
136. Liao R, Jain M, Cui L, D’Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106: 2125-2131, 2002. doi:10.1161/01.CIR.0000034049.61181.F3.
137. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 78: 893-902, 1996. doi:10.1161/01.RES.78.5.893.
138. Lindenmayer GE, Sordahl LA, Harigaya S, Allen JC, Besch HR Jr, Schwartz A. Some biochemical studies on subcellular systems isolated from fresh recipient human cardiac tissue obtained during transplantation. Am J Cardiol 27: 277-283, 1971. doi:10.1016/0002-9149(71)90303-1.
139. Liu J, Wang C, Murakami Y, Gong G, Ishibashi Y, Prody C, Ochiai K, Bache RJ, Godinot C, Zhang J. Mitochondrial ATPase and highenergy phosphates in failing hearts. Am J Physiol Heart Circ Physiol 281: H1319-H1326, 2001.
140. Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258, 2010. doi:10.1152/physrev.00015.2009.
141. Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24: 200-202, 2016. doi:10.1016/j.cmet.2016.07.018.
142. Lu T-M, Tsai J-Y, Chen Y-C, Huang C-Y, Hsu H-L, Weng C-F, Shih C-C, Hsu C-P. Downregulation of Sirt1 as aging change in advanced heart failure. J Biomed Sci 21: 57, 2014. doi:10.1186/1423-0127-21-57.
143. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferatoractivated receptor-α-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112: 2339-2346, 2005. doi:10.1161/CIRCULATIONAHA.105.534594.
144. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsey RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res 53: 841-851, 2002. doi:10.1016/S0008-6363(01)00560-0.
145. Lygate CA, Aksentijevic D, Dawson D, ten Hove M, Phillips D, de Bono JP, Medway DJ, Sebag-Montefiore L, Hunyor I, Channon KM, Clarke K, Zervou S, Watkins H, Balaban RS, Neubauer S. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ Res 112: 945-955, 2013. doi:10.1161/CIRCRESAHA.112.300725.
146. Lygate CA, Bohl S, ten Hove M, Faller KME, Ostrowski PJ, Zervou S, Medway DJ, Aksentijevic D, Sebag-Montefiore L, Wallis J, Clarke K, Watkins H, Schneider JE, Neubauer S. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res 96: 466-475, 2012. doi:10.1093/cvr/cvs272.
147. Lygate CA, Fischer A, Sebag-Montefiore L, Wallis J, ten Hove M, Neubauer S. The creatine kinase energy transport system in the failing mouse heart. J Mol Cell Cardiol 42: 1129-1136, 2007. doi:10.1016/j. yjmcc.2007.03.899.
148. Lygate CA, Medway DJ, Ostrowski PJ, Aksentijevic D, Sebag-Montefiore L, Hunyor I, Zervou S, Schneider JE, Neubauer S. Chronic creatine kinase deficiency eventually leads to congestive heart failure, but severity is dependent on genetic background, gender and age. Basic Res Cardiol 107: 276, 2012. doi:10.1007/s00395-012-0276-2.
149. Lygate CA, Neubauer S. The myocardial creatine kinase system in the normal, ischaemic and failing heart. In: Cardiac Energy Metabolism in Health and Disease, edited by Lopaschuk DG, Dhalla SN. New York:Springer, 2014, p. 155-168.
150. Mahmod M, Francis JM, Pal N, Lewis A, Dass S, De Silva R, Petrou M, Sayeed R, Westaby S, Robson MD, Ashrafian H, Neubauer S, Karamitsos TD. Myocardial perfusion and oxygenation are impaired during stress in severe aortic stenosis and correlate with impaired energetics and subclinical left ventricular dysfunction. J Cardiovasc Magn Reson 16: 29, 2014. doi:10.1186/1532-429X-16-29.
151. Marín-García J, Goldenthal MJ, Damle S, Pi Y, Moe GW. Regional distribution of mitochondrial dysfunction and apoptotic remodeling in pacing-induced heart failure. J Card Fail 15: 700-708, 2009. doi:10.1016/j.cardfail.2009.04.010.
152. Martín MA, Gómez MA, Guillén F, Börnstein B, Campos Y, Rubio JC, de la Calzada CS, Arenas J. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 1502: 330-336, 2000. doi:10.1016/S0925-4439(00)00061-2.
153. Masoud WGT, Ussher JR, Wang W, Jaswal JS, Wagg CS, Dyck JR, Lygate CA, Neubauer S, Clanachan AS, Lopaschuk GD. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res 101:30-38, 2014. doi:10.1093/cvr/cvt216.
154. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, White FC. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 91: 1814-1823, 1995. doi:10.1161/01.CIR.91.6.1814.
155. Matas J, Young NT, Bourcier-Lucas C, Ascah A, Marcil M, Deschepper CF, Burelle Y. Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J Mol Cell Cardiol 46: 420-430, 2009. doi:10.1016/j.yjmcc.2008.10.020.
156. Maurer I, Zierz S. Myocardial respiratory chain enzyme activities in idiopathic dilated cardiomyopathy, and comparison with those in atherosclerotic coronary artery disease and valvular aortic stenosis. Am J Cardiol 72: 428-433, 1993. doi:10.1016/0002-9149(93)91135-5.
157. Maurer I, Zierz S. Positive correlation between aortic valve pressure gradient and mitochondrial respiratory chain capacity in hypertrophied human left ventricle. Clin Investig 70: 896-901, 1992. doi:10.1007/BF00180435.
158. Meng R, Pei Z, Zhang A, Zhou Y, Cai X, Chen B, Liu G, Mai W, Wei J, Dong Y. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway. Arch Biochem Biophys 511: 1-7, 2011. doi:10.1016/j.abb.2011.04.010.
159. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF-α inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 287: H1813-H1820, 2004. doi:10.1152/ajpheart.00036.2004.
160. Mootha VK, Arai AE, Balaban RS. Maximum oxidative phosphorylation capacity of the mammalian heart. Am J Physiol Heart Circ Physiol 272: H769-H775, 1997.
161. Muoio DM, Noland RC, Kovalik J-P, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, Kheterpal I, Zhang J, Covington JD, Bajpeyi S, Ravussin E, Kraus W, Koves TR, Mynatt RL. Musclespecific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab 15: 764-777, 2012. doi:10.1016/j.cmet.2012.04.005.
162. Murakami Y, Zhang J, Eijgelshoven MHJ, Chen W, Carlyle WC, Zhang Y, Gong G, Bache RJ. Myocardial creatine kinase kinetics in hearts with postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol 276: H892-H900, 1999.
163. Murakami Y, Zhang Y, Cho YK, Mansoor AM, Chung JK, Chu C, Francis G, Ugurbil K, Bache RJ, From AHL, Jerosch-Herold M, Wilke N, Zhang J. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Circulation 99: 942-948, 1999. doi:10.1161/01.CIR.99.7.942.
164. Murray AJ, Lygate CA, Cole MA, Carr CA, Radda GK, Neubauer S, Clarke K. Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart. Cardiovasc Res 71: 149-157, 2006. doi:10.1016/j.cardiores.2006.02.031.
165. Nahrendorf M, Spindler M, Hu K, Bauer L, Ritter O, Nordbeck P, Quaschning T, Hiller K-H, Wallis J, Ertl G, Bauer WR, Neubauer S. Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarction. Cardiovasc Res 65: 419-427, 2005. doi:10.1016/j.cardiores.2004.10.006.
166. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, Takahashi M, Morikawa S, Inubushi T, Nakamura Y, Kinoshita M, Horie M. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 42: 1587-1593, 2003. doi:10.1016/j.jacc.2003.05.005.
167. Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation 91: 1824-1833, 1995. doi:10.1161/01.CIR.91.6.1824.
168. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, Tian R. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44: 662-667, 2004. doi:10.1161/01.HYP.0000144292.69599.0c.
169. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD. Creatine kinase system in failing and nonfailing human myocardium. Circulation 94: 1894-1901, 1996. doi:10.1161/01.CIR.94.8.1894.
170. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, Gastaldelli A, Ciociaro D, Pellegrini P, Testa R, Menichetti L, L’Abbate A, Stanley WC, Recchia FA. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 293:H3270-H3278, 2007. doi:10.1152/ajpheart.00887.2007.
171. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med 356:1140-1151, 2007. doi:10.1056/NEJMra063052.
172. Neubauer S, Frank M, Hu K, Remkes H, Laser A, Horn M, Ertl G, Lohse MJ. Changes of creatine kinase gene expression in rat heart post-myocardial infarction. J Mol Cell Cardiol 30: 803-810, 1998. doi:10.1006/jmcc.1998.0645.
173. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190-2196, 1997. doi:10.1161/01.CIR.96.7.2190.
174. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M, Friedrich J, Gaudron P, Schnackerz K, Ingwall JS. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 95: 1092-1100, 1995. doi:10.1172/JCI117756.
175. 31 P-magnetic resonance spectroscopy. J Investig Med 45: 453-462, 1997.
176. 31 P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86: 1810-1818, 1992. doi:10.1161/01.CIR.86.6.1810.
177. +-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100: 1847-1850, 1999. doi:10.1161/01.CIR.100.18.1847.
178. Nikolaidis LA, Poornima I, Parikh P, Magovern M, Shen Y-T, Shannon RP. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol 47: 1871-1881, 2006. doi:10.1016/j.jacc.2005.11.082.
179. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen Y-T, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61: 297-306, 2004. doi:10.1016/j.cardiores.2003.11.027.
180. Ning X-H, Zhang J, Liu J, Ye Y, Chen S-H, From AHL, Bache RJ, Portman MA. Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol 36: 282-287, 2000. doi:10.1016/S0735-1097(00)00689-6.
181. O’Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol 44: 315-322, 2008. doi:10.1016/j.yjmcc.2007.11.006.
182. Oliveira SM, Zhang YH, Solis RS, Isackson H, Bellahcene M, Yavari A, Pinter K, Davies JK, Ge Y, Ashrafian H, Walker JW, Carling D, Watkins H, Casadei B, Redwood C. AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res 110: 1192-1201, 2012. doi:10.1161/ CIRCRESAHA.111.259952.
183. Osbakken M, Douglas PS, Ivanics T, Zhang DN, Van Winkle T. Creatinine kinase kinetics studied by phosphorus-31 nuclear magnetic resonance in a canine model of chronic hypertension-induced cardiac hypertrophy. J Am Coll Cardiol 19: 223-228, 1992. doi:10.1016/0735-1097(92)90076-Y.
184. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-α in pacing-induced heart failure. Circulation 106: 606-612, 2002. doi:10.1161/01.CIR.0000023531.22727.C1.
185. Oudman I, Clark JF, Brewster LM. The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review. PLoS One 8: e52879, 2013. doi:10.1371/journal.pone.0052879.
186. Ozcan C, Bienengraeber M, Hodgson DM, Mann DL, Terzic A. Mitochondrial tolerance to stress impaired in failing heart. J Mol Cell Cardiol 35: 1161-1166, 2003. doi:10.1016/S0022-2828(03)00204-9.
187. Park SJ, Zhang J, Ye Y, Ormaza S, Liang P, Bank AJ, Miller LW, Bache RJ. Myocardial creatine kinase expression after left ventricular assist device support. J Am Coll Cardiol 39: 1773-1779, 2002. doi:10.1016/S0735-1097(02)01860-0.
188. Paternostro G, Clarke K, Heath J, Seymour A-ML, Radda GK. Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart. Cardiovasc Res 30: 205-211, 1995. doi:10.1016/S0008-6363(95)00019-4.
189. Planavila A, Laguna JC, Vázquez-Carrera M. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 280: 17464-17471, 2005. doi:10.1074/jbc.M414220200.
190. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF, Taegtmeyer H, O’Donnell JM, Lewandowski ED. Substrateenzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res 104: 805-812, 2009. doi:10.1161/CIRCRESAHA.108.189951.
191. Power ASC, Pham T, Loiselle DS, Crossman DH, Ward M-L, Hickey AJ. Impaired ADP channeling to mitochondria and elevated reactive oxygen species in hypertensive hearts. Am J Physiol Heart Circ Physiol 310: H1649-H1657, 2016. doi:10.1152/ajpheart.00050.2016.
192. Pulinilkunnil T, He H, Kong D, Asakura K, Peroni OD, Lee A, Kahn BB. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 286: 8798-8809, 2011. doi:10.1074/ jbc.M111.218719.
193. Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, Young ME, Dyck JRB. Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int J Obes 38: 205-215, 2014. doi:10.1038/ijo.2013.103.
194. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263-283, 1998. doi:10.1002/(SICI)1099-0895(199812)14:4263::AID-DMR233_3.0.CO;2-C.
195. Rayner JJ, Neubauer S, Rider OJ. The paradox of obesity cardiomyopathy and the potential for weight loss as a therapy. Obes Rev 16:679-690, 2015. doi:10.1111/obr.12292.
196. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104: 2923-2931, 2001. doi:10.1161/hc4901.100526.
197. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83: 969-979, 1998. doi:10.1161/01.RES.83.10.969.
198. Revis NW, Cameron AJV. Metabolism of lipids in experimental hypertrophic hearts of rabbits. Metabolism 28: 601-613, 1979. doi:10.1016/0026-0495(79)90011-8.
199. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira AB, Doenst T, Medina-Gomez G, Litwin SE, Lelliott CJ, Vidal-Puig A, Abel ED. PGC-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 109: 783-793, 2011. doi:10.1161/CIRCRESAHA.111.243964.
200. Rimbaud S, Sanchez H, Garnier A, Fortin D, Bigard X, Veksler V, Ventura-Clapier R. Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol 46: 952-959, 2009. doi:10.1016/ j.yjmcc.2009.01.013.
201. Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res 113: 411-421, 2017. doi:10.1093/cvr/cvx017.
202. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 α and SIRT1 pathways. FEBS Lett 582:46-53, 2008. doi:10.1016/j.febslet.2007.11.034.
203. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118, 2005. doi:10.1038/ nature03354.
204. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, Terrand J, Lerch R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc Res 52: 407-416, 2001. doi:10.1016/S0008-6363(01)00393-5.
205. Rowe GC, Jiang A, Arany Z. PGC-1 coactivators in cardiac development and disease. Circ Res 107: 825-838, 2010. doi:10.1161/ CIRCRESAHA.110.223818.
206. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stagedependent manner. Circ Res 94: 525-533, 2004. doi:10.1161/01.RES.0000117088.36577.EB.
207. Russell RR III, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest 87: 384-390, 1991. doi:10.1172/JCI115008.
208. Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503, 2004. doi:10.1172/JCI19297.
209. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837-2842, 1996. doi:10.1161/01.CIR.94.11.2837.
210. Saks V, Dzeja P, Schlattner U, Vendelin M, Terzic A, Wallimann T. Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol 571: 253-273, 2006. doi:10.1113/jphysiol.2005.101444.
211. Saks V, Kuznetsov AV, Gonzalez-Granillo M, Tepp K, Timohhina N, Karu-Varikmaa M, Kaambre T, Dos Santos P, Boucher F, Guzun R. Intracellular Energetic Units regulate metabolism in cardiac cells. J Mol Cell Cardiol 52: 419-436, 2012. doi:10.1016/j.yjmcc.2011.07.015.
212. Saks VA, Belikova YO, Kuznetsov AV, Khuchua ZA, Branishte TH, Semenovsky ML, Naumov VG. Phosphocreatine pathway for energy transport: ADP diffusion and cardiomyopathy. Am J Physiol 261, Suppl 4: 30-38, 1991.
213. Sanbe A, Tanonaka K, Kobayasi R, Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 27: 2209-2222, 1995. doi:10.1016/ S0022-2828(95)91551-6.
214. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N, Kitakaze M. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 119: 2568-2577, 2009. doi:10.1161/ CIRCULATIONAHA.108.798561.
215. Saupe KW, Spindler M, Hopkins JCA, Shen W, Ingwall JS. Kinetic, thermodynamic, and developmental consequences of deleting creatine kinase isoenzymes from the heart. Reaction kinetics of the creatine kinase isoenzymes in the intact heart. J Biol Chem 275: 19742-19746, 2000. doi:10.1074/jbc.M001932200.
216. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ Res 82: 898-907, 1998. doi:10.1161/01.RES.82.8.898.
217. Scheubel RJ, Tostlebe M, Simm A, Rohrbach S, Prondzinsky R, Gellerich FN, Silber RE, Holtz J. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol 40: 2174-2181, 2002. doi:10.1016/S0735-1097(02)02600-1.
218. Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 1762:164-180, 2006. doi:10.1016/j.bbadis.2005.09.004.
219. Schönekess BO, Allard MF, Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77: 726-734, 1995. doi:10.1161/01.RES.77.4.726.
220. 13 C magnetic resonance study. Circ Cardiovasc Imaging 5: 201-209, 2012. doi:10.1161/CIRCIMAGING.111.969451.
221. Schugar RC, Moll AR, André d’Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab 3:754-769, 2014. doi:10.1016/j.molmet.2014.07.010.
222. Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi E, Zani M, Feccia M, Mancini M, Petrozza V, Cossarizza A, Gallo P, Taylor RW, d’Amati G. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 50:1362-1369, 2007. doi:10.1016/j.jacc.2007.06.035.
223. Seymour A-ML, Giles L, Ball V, Miller JJ, Clarke K, Carr CA, Tyler DJ. In vivo assessment of cardiac metabolism and function in the abdominal aortic banding model of compensated cardiac hypertrophy. Cardiovasc Res 106: 249-260, 2015. doi:10.1093/cvr/cvv101.
224. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 32: 2361-2367, 2000. doi:10.1006/jmcc.2000.1266.
225. Sheeran FL, Pepe S. Posttranslational modifications and dysfunction of mitochondrial enzymes in human heart failure. Am J Physiol Endocrinol Metab 311: E449-E460, 2016. doi:10.1152/ajpendo.00127.2016.
226. Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF, Ingwall JS. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 100: 2113-2118, 1999. doi:10.1161/01.CIR.100.20.2113.
227. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, Ryan TP, Ingwall JS. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol 39:537-544, 2005. doi:10.1016/j.yjmcc.2005.05.003.
228. Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ. PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46: 201-212, 2009. doi:10.1016/j.yjmcc.2008.10.025.
229. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114: 1151-1158, 2006. doi:10.1161/CIRCULATIONAHA.106.613646.
230. Smith SH, Kramer MF, Reis I, Bishop SP, Ingwall JS. Regional changes in creatine kinase and myocyte size in hypertensive and nonhy-pertensive cardiac hypertrophy. Circ Res 67: 1334-1344, 1990. doi:10.1161/01.RES.67.6.1334.
231. Soltys C-LM, Kovacic S, Dyck JRB. Activation of cardiac AMPactivated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 290:H2472-H2479, 2006. doi:10.1152/ajpheart.01206.2005.
232. Sordahl LA, McCollum WB, Wood WG, Schwartz A. Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. Am J Physiol 224: 497-502, 1973.
233. Sorokina N, O’Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115: 2033-2041, 2007. doi:10.1161/CIRCULATIONAHA.106.668665.
234. Spindler M, Niebler R, Remkes H, Horn M, Lanz T, Neubauer S. Mitochondrial creatine kinase is critically necessary for normal myocardial high-energy phosphate metabolism. Am J Physiol Heart Circ Physiol 283: H680-H687, 2002. doi:10.1152/ajpheart.00800.2001.
235. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005. doi:10.1152/physrev.00006.2004.
236. Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Køber L, Dela F. Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail 15: 150-157, 2013. doi:10.1093/eurjhf/ hfs172.
237. Strøm CC, Aplin M, Ploug T, Christoffersen TEH, Langfort J, Viese M, Galbo H, Haunsø S, Sheikh SP. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 272: 2684-2695, 2005. doi:10.1111/j.1742-4658.2005.04684.x.
238. Suga H. Ventricular energetics. Physiol Rev 70: 247-277, 1990.
239. Sung MM, Zordoky BN, Bujak AL, Lally JSV, Fung D, Young ME, Horman S, Miller EJ, Light PE, Kemp BE, Steinberg GR, Dyck JRB. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc Res 107:235-245, 2015. doi:10.1093/cvr/cvv166.
240. Taegtmeyer H. Genetics of energetics: transcriptional responses in cardiac metabolism. Ann Biomed Eng 28: 871-876, 2000. doi:10.1114/1.1312187.
241. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 1015: 202-213, 2004. doi:10.1196/ annals.1302.017.
242. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 11: 416-426, 1988. doi:10.1161/01.HYP.11.5.416.
243. Taegtmeyer H, Roberts AFC, Raine AE. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. J Am Coll Cardiol 6: 864-870, 1985. doi:10.1016/S0735-1097(85)80496-4.
244. Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, Des Rosiers C, Gerszten R, Glatz JF, Griffin JL, Gropler RJ, Holzhuetter H-G, Kizer JR, Lewandowski ED, Malloy CR, Neubauer S, Peterson LR, Portman MA, Recchia FA, Van Eyk JE, Wang TJ; American Heart Association Council on Basic Cardiovascular Sciences. Assessing cardiac metabolism: a scientific statement from the American Heart Association. Circ Res 118: 1659-1701, 2016. doi:10.1161/RES.0000000000000097.
245. Tang Y, Mi C, Liu J, Gao F, Long J. Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat. Cardiovasc Pathol 23: 101-106, 2014. doi:10.1016/j.carpath.2013.11.002.
246. Ten Hove M, Chan S, Lygate C, Monfared M, Boehm E, Hulbert K, Watkins H, Clarke K, Neubauer S. Mechanisms of creatine depletion in chronically failing rat heart. J Mol Cell Cardiol 38: 309-313, 2005. doi:10.1016/j.yjmcc.2004.11.016.
247. Ten Hove M, Lygate CA, Fischer A, Schneider JE, Sang AE, Hulbert K, Sebag-Montefiore L, Watkins H, Clarke K, Isbrandt D, Wallis J, Neubauer S. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferase-knockout mice. Circulation 111: 2477-2485, 2005. doi:10.1161/01.CIR.0000165147.99592.01.
248. Tian R, Christe ME, Spindler M, Hopkins JC, Halow JM, Camacho SA, Ingwall JS. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 99: 745-751, 1997. doi:10.1172/JCI119220.
249. 2+ handling contributes to decreased contractile reserve in rat hearts. Am J Physiol Heart Circ Physiol 275: H2064-H2071, 1998.
250. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol Heart Circ Physiol 270: H1207-H1216, 1996.
251. Tian R, Musi N, D’Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104: 1664-1669, 2001. doi:10.1161/hc4001.097183.
252. Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96: 1313-1319, 1997. doi:10.1161/01.CIR.96.4.1313.
253. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol 28:755-765, 1996. doi:10.1006/jmcc.1996.0070.
254. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. In: Methods Enzymol. New York:Academic, 1996, p. 484-509.
255. Tuunanen H, Engblom E, Naum A, Någren K, Hesse B, Airaksinen KEJ, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114: 2130-2137, 2006. doi:10.1161/ CIRCULATIONAHA.106.645184.
256. Tuunanen H, Engblom E, Naum A, Scheinin M, Någren K, Airaksinen J, Nuutila P, Iozzo P, Ukkonen H, Knuuti J. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy:evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 12: 644-652, 2006. doi:10.1016/j. cardfail.2006.06.005.
257. Unverferth DV, Lee SW, Wallick ET. Human myocardial adenosine triphosphatase activities in health and heart failure. Am Heart J 115:139-146, 1988. doi:10.1016/0002-8703(88)90529-7.
258. van Bilsen M, van der Vusse GJ, Reneman RS. Transcriptional regulation of metabolic processes: implications for cardiac metabolism. Pflugers Arch 437: 2-14, 1998. doi:10.1007/s004240050739.
259. Vega RB, Horton JL, Kelly DP. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ Res 116: 1820-1834, 2015. doi:10.1161/CIRCRESAHA.116.305420.
260. Vendelin M, Hoerter JA, Mateo P, Soboll S, Gillet B, Mazet J-L. Modulation of energy transfer pathways between mitochondria and myofibrils by changes in performance of perfused heart. J Biol Chem 285: 37240-37250, 2010. doi:10.1074/jbc.M110.147116.
261. Ventura-Clapier R, Garnier A, Veksler V, Joubert F. Bioenergetics of the failing heart. Biochim Biophys Acta 1813: 1360-1372, 2011. doi:10.1016/j.bbamcr.2010.09.006.
262. Vianna CR, Huntgeburth M, Coppari R, Choi CS, Lin J, Krauss S, Barbatelli G, Tzameli I, Kim Y-B, Cinti S, Shulman GI, Spiegelman BM, Lowell BB. Hypomorphic mutation of PGC-1β causes mitochondrial dysfunction and liver insulin resistance. Cell Metab 4: 453-464, 2006. doi:10.1016/j.cmet.2006.11.003.
263. Viollet B, Andreelli F, Jørgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JFP, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111: 91-98, 2003. doi:10.1172/JCI16567.
264. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the ‘phosphocreatine circuit’ for cellular energy homeostasis. Biochem J 281: 21-40, 1992. doi:10.1042/bj2810021.
265. Walther T, Tschöpe C, Sterner-Kock A, Westermann D, Heringer-Walther S, Riad A, Nikolic A, Wang Y, Ebermann L, Siems W-E, Bader M, Shakibaei M, Schultheiss H-P, Dörner A. Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease. Circulation 115: 333-344, 2007. doi:10.1161/CIRCULATIONAHA.106.643296.
266. Watanabe S, Horie T, Nagao K, Kuwabara Y, Baba O, Nishi H, Sowa N, Narazaki M, Matsuda T, Takemura G, Wada H, Hasegawa K, Kimura T, Ono K. Cardiac-specific inhibition of kinase activity in calcium/calmodulin-dependent protein kinase kinase-β leads to accelerated left ventricular remodeling and heart failure after transverse aortic constriction in mice. PLoS One 9: e108201, 2014. doi:10.1371/journal. pone.0108201.
267. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA 102: 808-813, 2005.
268. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51:93-102, 2008. doi:10.1016/j.jacc.2007.10.021.
269. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, Goodyear LJ, Tian R. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit of AMP-activated protein kinase. J Biol Chem 278: 28372-28377, 2003. doi:10.1074/jbc. M303521200.
270. Xiong Q, Zhang P, Guo J, Swingen C, Jang A, Zhang J. Myocardial ATP hydrolysis rates in vivo: a porcine model of pressure overloadinduced hypertrophy. Am J Physiol Heart Circ Physiol 309: H450-H458, 2015. doi:10.1152/ajpheart.00072.2015.
271. Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119: 2818-2828, 2009. doi:10.1161/CIRCULATIONAHA.108.832915.
272. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100: 1208-1217, 2007. doi:10.1161/01.RES.0000264104.25265.b6.
273. Ye Y, Gong G, Ochiai K, Liu J, Zhang J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103: 1570-1576, 2001. doi:10.1161/01.CIR.103.11.1570.
274. Ye Y, Wang C, Zhang J, Cho YK, Gong G, Murakami Y, Bache RJ. Myocardial creatine kinase kinetics and isoform expression in hearts with severe LV hypertrophy. Am J Physiol Heart Circ Physiol 281: H376-H386, 2001.
275. Yin M, van der Horst ICC, van Melle JP, Qian C, van Gilst WH, Silljé HHW, de Boer RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 301: H459-H468, 2011. doi:10.1152/ajpheart.00054.2011.
276. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276: 44390-44395, 2001. doi:10.1074/jbc.M103826200.
277. Zaha VG, Qi D, Su KN, Palmeri M, Lee HY, Hu X, Wu X, Shulman GI, Rabinovitch PS, Russell RR III, Young LH. AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia. J Mol Cell Cardiol 91: 104-113, 2016. doi:10.1016/j.yjmcc.2015.12.032.
278. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res 111: 800-814, 2012. doi:10.1161/CIRCRESAHA.111.255505.
279. Zarrinpashneh E, Beauloye C, Ginion A, Pouleur A-C, Havaux X, Hue L, Viollet B, Vanoverschelde J-L, Bertrand L. AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun 376: 677-681, 2008. doi:10.1016/j.bbrc.2008.09.057.
280. 2-isoform of AMPactivated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol 291: H2875-H2883, 2006. doi:10.1152/ajpheart.01032.2005.
281. Zervou S, Ray T, Sahgal N, Sebag-Montefiore L, Cross R, Medway DJ, Ostrowski PJ, Neubauer S, Lygate CA. A role for thioredoxininteracting protein (Txnip) in cellular creatine homeostasis. Am J Physiol Endocrinol Metab 305: E263-E270, 2013. doi:10.1152/ajpendo.00637.2012.
282. Zervou S, Whittington HJ, Russell AJ, Lygate CA. Augmentation of Creatine in the Heart. Mini Rev Med Chem 16: 19-28, 2016. doi:10.2174/1389557515666150722102151.
283. Zhabyeyev P, Gandhi M, Mori J, Basu R, Kassiri Z, Clanachan A, Lopaschuk GD, Oudit GY. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res 97: 676-685, 2013. doi:10.1093/cvr/cvs424.
284. Zhang J, Duncker DJ, Ya X, Zhang Y, Pavek T, Wei H, Merkle H, Uğurbil K, From AHL, Bache RJ. Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake. A 31P NMR spectroscopic study. Circulation 92: 1274-1283, 1995. doi:10.1161/01.CIR.92.5.1274.
285. Zhang J, Murakami Y, Zhang Y, Cho YK, Ye Y, Gong G, Bache RJ, Ug?urbil K, From AHL. Oxygen delivery does not limit cardiac performance during high work states. Am J Physiol Heart Circ Physiol 277:H50-H57, 1999.
286. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, Lopaschuk GD. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail 6: 1039-1048, 2013. doi:10.1161/CIRCHEARTFAILURE.112.000228.
287. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, Bache RJ, Chen Y. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52: 918-924, 2008. doi:10.1161/HYPERTENSIONAHA.108.114702.